Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07265807 in Advanced or Metastatic Solid Tumors
NCT04458259Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Sep 2020
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of pf-07265807 in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 2 more (7 arms), sponsored by Pfizer. Primary endpoints: Dose Limiting Toxicities at day 42, Treatment Emergent Adverse Events at 2 years and 3 more. Started Sep 2020; status: terminated.
02
Drugs
pf-07265807
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)gastric cancer (GC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04458259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04458259.